Honda of America will offer two all-electric SUVs in the US in 2024 and offer hybrid gas-electric vehicles to comply with emissions-reduction targets and cope with California's ban on sales of new internal-combustion vehicles by 2035.
According to Honda of America sales chief Dave Gardner, one of the electric SUVs will be from the Honda brand, and the other an Acura.
The company already has a hybrid car called the Insight as well as hybrid versions of its Accord and CR-V. The new vehicles' underpinnings will come from a partnership with GM.
Honda will also reduce emissions from its internal combustion vehicles, Gardner added.
Gardner conceded that they are not leading the electric vehicle race and are good at things that seem to be going out of vogue.
He added that "there’s no doubt" that they have to start moving quickly toward attaining zero emissions.
Gardner wouldn’t say when Honda will go all-electric and noted that the company is focused on achieving carbon-neutrality by 2050 and is aware that President Joe Biden is focused on zero emissions.


AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion
Alphabet Eyes First Australian Dollar Bond as AI Spending Drives Funding Push
BofA Sees Micron EPS Topping $230 by 2030, Backs Major Stock Upside
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports
Standard Chartered Expands Hedge Fund Access for Wealth Clients
SK Hynix Shares Surge on Record $28.6 Billion Buyback
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks
Shein Targets $26B-$27B Valuation for Hong Kong IPO
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised
Anthropic Revenue Run Rate Hits $65 Billion as IPO Plans Accelerate
Google to Buy Spirit Airlines Business Data for $10 Million to Train AI
Coty Revenue Beats Estimates as Beauty Demand Holds Firm
Schott Pharma Stock Rises as Barclays Upgrades Rating on Growth Outlook




